Manager TitleAgeSince
Chief Executive Officer - 2016-08-17
Chief Operating Officer - -
Corporate Officer/Principal - 2022-04-04
Director TitleAgeSince
Chairman 59 -
Director/Board Member 64 2025-09-11
Date Insider Type Main position Quantity % Market Cap.
24-07-18Free

Chief Financial Officer

4,000,000 2.3947%
24-07-03Sell

Director

4,350,000 2.6043%
24-07-03Buy

Director

550,000 0.3293%
Change 5-day change 1-year change 3-year change Capi.($)
-.--%+3.45% - - 4.02M
+3.49%+1.36%-29.04%-11.02% 166B
+5.04%+2.73%-5.88%-4.53% 106B
+2.80%+3.63%+0.09%+55.31% 57.69B
+1.33%+1.39%+53.16%+49.84% 53.78B
+3.39%+1.39%-10.26%-39.65% 43.56B
+3.50%+11.11% - - 36.52B
+3.47%+1.58%-14.08%-43.91% 27.49B
+0.20%+4.24%+64.56%-3.33% 25.84B
+2.78%+1.17%-8.15%-0.43% 21.27B
Average +2.60%+4.67%+6.30%+0.29% 59.87B
Weighted average by Cap. +3.31%+3.80%-3.84%+1.05%
Logo Belluscura plc
Belluscura PLC is a United Kingdom-based medical device developer company. The Company is focused on developing lightweight and portable oxygen enrichment technology. The Company's product X-PLOR, is a modular portable oxygen concentrator. The X-PLOR is lightweight, specifically designed to replace metal oxygen tanks and heavier portable oxygen concentrator devices. The X-PLOR can deliver up to 95% pure oxygen to patients 24 hours a day, seven days a week. The Company is focused on developing medical devices who suffer from chronic lung diseases, such as the Chronic Obstructive Pulmonary Disease (COPD), respiratory distress caused by COVID-19, and many other respiratory disorders. It is also focused on developing, licensing and manufacturing portable oxygen concentrators for use in treating lung diseases with its oxygen platform technologies, to include recreational and industrial oxygen concentrators, wound care devices, drug delivery devices and more.
Employees
35
  1. Stock Market
  2. Stocks
  3. BELL Stock